A company still losing money, with high risk. Institutions are adding.
Facts from SEC filings, not a recommendation.
From PCVX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Last 12 months: -$298.4M.
Price chart by TradingView.
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: net margin 10%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
SEC filings of any kind. 50 means a normal week.
Institutions added 2.1% to their holdings. 178 bought, 149 sold. 3 quarters of net buying in a row.
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|---|---|---|---|---|---|
Elvia CowanSVP, Finance & CAO | Sell | 19K | $86.74 | $1.6M | 28K | Oct 5Filing ↗ |
| ||||||
Jim WassilEVP, Chief Scientific Ofc, COO | Sell | 18K | $86.74 | $1.6M | 145K | Oct 5Filing ↗ |
| ||||||
Jim WassilEVP, Chief Scientific Ofc, COO | Sell | 2K | $56.67 | $128K | 145K | Oct 1Filing ↗ |
| ||||||
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
19,000 shares at $86.74 · $1.6M
18,000 shares at $86.74 · $1.6M
2,250 shares at $56.67 avg ($56.65 to $57.09) · $128K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page